386 related articles for article (PubMed ID: 33945380)
21. Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
Garon EB; Brodrick P
Drugs; 2021 Apr; 81(5):547-554. PubMed ID: 33638808
[TBL] [Abstract][Full Text] [Related]
22. [Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation].
Basse C; Régaldo-Saint Blancard L
Bull Cancer; 2023 Sep; 110(9):869-871. PubMed ID: 37442707
[No Abstract] [Full Text] [Related]
23. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
[TBL] [Abstract][Full Text] [Related]
24. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
[TBL] [Abstract][Full Text] [Related]
25. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
[TBL] [Abstract][Full Text] [Related]
26. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
[TBL] [Abstract][Full Text] [Related]
27. Going After
Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
[TBL] [Abstract][Full Text] [Related]
28. Molecular therapeutic targets in non-small cell lung cancer.
Sankar K; Gadgeel SM; Qin A
Expert Rev Anticancer Ther; 2020 Aug; 20(8):647-661. PubMed ID: 32580596
[TBL] [Abstract][Full Text] [Related]
29. MET alterations in advanced non-small cell lung cancer.
Sakamoto M; Patil T
Lung Cancer; 2023 Apr; 178():254-268. PubMed ID: 36924573
[TBL] [Abstract][Full Text] [Related]
30. Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations.
Yamaguchi M; Hirai S; Idogawa M; Uchida H; Sakuma Y
Exp Cell Res; 2022 Apr; 413(2):113078. PubMed ID: 35189107
[TBL] [Abstract][Full Text] [Related]
31. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo G; Bahcall M; Spurr LF; Che J; Ricciuti B; Leonardi GC; Lo YC; Li YY; Lamberti G; Nguyen T; Milan MSD; Venkatraman D; Umeton R; Paweletz CP; Albayrak A; Cherniack AD; Price KS; Fairclough SR; Nishino M; Sholl LM; Oxnard GR; Jänne PA; Awad MM
Clin Cancer Res; 2020 Jun; 26(11):2615-2625. PubMed ID: 32034073
[TBL] [Abstract][Full Text] [Related]
32. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
33. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
Shimokawa M; Nosaki K; Seto T; Ohashi K; Morise M; Horinouchi H; Sakakibara J; Murakami H; Yano S; Satouchi M; Matsumoto S; Goto K; Yoh K
Trials; 2020 Mar; 21(1):298. PubMed ID: 32228679
[TBL] [Abstract][Full Text] [Related]
34. Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
Riedel R; Fassunke J; Tumbrink HL; Scheel AH; Heydt C; Hieggelke L; Scheffler M; Heimsoeth A; Nogova L; Michels S; Weber JP; Fischer RN; Eisert A; Westphal T; Schaufler D; Siemanowski J; Ihle MA; Wagener-Ryczek S; Castiglione R; Pappesch R; Rehker J; Jürgens J; Stoelben E; Bunck A; Kobe C; Merkelbach-Bruse S; Sos ML; Büttner R; Wolf J
Eur J Cancer; 2023 Jan; 179():124-135. PubMed ID: 36521334
[TBL] [Abstract][Full Text] [Related]
35. Targeting un-MET needs in advanced non-small cell lung cancer.
Coleman N; Harbery A; Heuss S; Vivanco I; Popat S
Lung Cancer; 2022 Feb; 164():56-68. PubMed ID: 35033939
[TBL] [Abstract][Full Text] [Related]
36. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
Salgia R
Mol Cancer Ther; 2017 Apr; 16(4):555-565. PubMed ID: 28373408
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
38. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
39. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
40. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
Kanemura H; Takeda M; Shimizu S; Nakagawa K
Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
